» Articles » PMID: 24161883

Genetic Variants in Selenoprotein P Plasma 1 Gene (SEPP1) Are Associated with Fasting Insulin and First Phase Insulin Response in Hispanics

Overview
Journal Gene
Specialty Molecular Biology
Date 2013 Oct 29
PMID 24161883
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Insulin resistance is not fully explained on a molecular level, though several genes and proteins have been tied to this defect. Knockdowns of the SEPP1 gene, which encodes the selenoprotein P (SeP) protein, have been shown to increase insulin sensitivity in mice. SeP is a liver-derived plasma protein and a major supplier of selenium, which is a proposed insulin mimetic and antidiabetic agent.

Objective: SEPP1 single nucleotide polymorphisms (SNPs) were selected for analysis with glucometabolic measures.

Participants And Measures: The study included1424 Hispanics from families in the Insulin Resistance Atherosclerosis Family Study (IRASFS). Additionally, the multi-ethnic Insulin Resistance Atherosclerosis Study was used. A frequently sampled intravenous glucose tolerance test was used to obtain precise measures of acute insulin response (AIR) and the insulin sensitivity index (SI).

Design: 21 SEPP1 SNPs (tagging SNPs (n=12) from HapMap, 4 coding variants and 6 SNPs in the promoter region) were genotyped and analyzed for association.

Results: Two highly correlated (r(2)=1) SNPs showed association with AIR (rs28919926; Cys368Arg; p=0.0028 and rs146125471; Ile293Met; p=0.0026) while rs16872779 (intronic) was associated with fasting insulin levels (p=0.0097). In the smaller IRAS Hispanic cohort, few of the associations seen in the IRASFS were replicated, but meta-analysis of IRASFS and all 3 IRAS cohorts (N=2446) supported association of rs28919926 and rs146125471 with AIR (p=0.013 and 0.0047, respectively) as well as rs7579 with SI (p=0.047).

Conclusions: Overall, these results in a human sample are consistent with the literature suggesting a role for SEPP1 in insulin resistance.

Citing Articles

The association of selenium exposure with the odds of metabolic syndrome: a dose-response meta-analysis.

Yuan R, Zhang Y, Han J BMC Endocr Disord. 2025; 25(1):49.

PMID: 39994710 PMC: 11853193. DOI: 10.1186/s12902-025-01858-8.


Unraveling the Link: Mendelian Randomization Reveals Causal Relationship Between Selenium and Metabolic Syndrome.

Liu F, Wang K, Nie J, Deng M Biol Trace Elem Res. 2024; 203(2):790-798.

PMID: 38776021 DOI: 10.1007/s12011-024-04237-x.


Genetic Determinants of Selenium Availability, Selenium-Response, and Risk of Polycystic Ovary Syndrome.

Sharma P, Khetarpal P Biol Trace Elem Res. 2024; 202(11):4843-4857.

PMID: 38227265 DOI: 10.1007/s12011-023-04052-w.


The role of hepatokines in NAFLD.

Stefan N, Schick F, Birkenfeld A, Haring H, White M Cell Metab. 2023; 35(2):236-252.

PMID: 36754018 PMC: 10157895. DOI: 10.1016/j.cmet.2023.01.006.


Selenium status and type 2 diabetes risk.

Huang Y, Combs Jr G, Wu T, Zeng H, Cheng W Arch Biochem Biophys. 2022; 730:109400.

PMID: 36122760 PMC: 9707339. DOI: 10.1016/j.abb.2022.109400.


References
1.
Burk R, Hill K, Motley A . Plasma selenium in specific and non-specific forms. Biofactors. 2001; 14(1-4):107-14. DOI: 10.1002/biof.5520140115. View

2.
Slattery M, Lundgreen A, Welbourn B, Corcoran C, Wolff R . Genetic variation in selenoprotein genes, lifestyle, and risk of colon and rectal cancer. PLoS One. 2012; 7(5):e37312. PMC: 3355111. DOI: 10.1371/journal.pone.0037312. View

3.
Schwarz K, FOLTZ C . Factor 3 activity of selenium compounds. J Biol Chem. 1958; 233(1):245-51. View

4.
Can B, Ulusu N, Kilinc K, Acan N, Saran Y, Turan B . Selenium treatment protects diabetes-induced biochemical and ultrastructural alterations in liver tissue. Biol Trace Elem Res. 2005; 105(1-3):135-50. DOI: 10.1385/bter:105:1-3:135. View

5.
Rayman M, Stranges S . Epidemiology of selenium and type 2 diabetes: can we make sense of it?. Free Radic Biol Med. 2013; 65:1557-1564. DOI: 10.1016/j.freeradbiomed.2013.04.003. View